Article

New approach possible to management of perforating ocular injuries

A new preventive approach to perforating ocular injuries seems to prevent the almost inevitable development of proliferative vitreoretinopathy (PVR) that follows this type of injury, according to Ferenc Kuhn, MD, PhD, of the University of Alabama, Birmingham.

New Orleans-A new preventive approach to perforating ocular injuries seems to prevent the almost inevitable development of proliferative vitreoretinopathy (PVR) that follows this type of injury, according to Ferenc Kuhn, MD, PhD, of the University of Alabama, Birmingham.

Standard treatment of perforating injuries includes closing the entrance wound during an initial surgery, a pars plana vitrectomy 6 to 10 days later to clear the hemorrhage and apply laser retinopexy around the exit wound. After the development of retinal detachment and PVR, another and possibly additional surgeries are needed to remove proliferative tissue.

Dr. Kuhn advised using a new approach during retina subspecialty day at the American Academy of Ophthalmology annual meeting.

"Prevent the PVR and retinal folds from developing," he said. In his treatment approach, he advised closing the entry and exit wounds and performing anterior segment manipulations. Postoperative care includes heavy topical occasionally systemic steroid therapy to minimize the inflammation. In a second surgery performed 3 days later, vitrectomy is then performed. Diathermy is applied around the exit wound involving the retina and the choroids.

Dr. Kuhn reported that in the five patients who have undergone this procedure, no PVR or retinal folds have developed.

"The traditional approach increases complications. The new approach should be offered as a better option to patients," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.